| Market Capitalization (Millions $) |
160 |
| Shares
Outstanding (Millions) |
37 |
| Employees |
130 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-62 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Molecular Partners AG is a biopharmaceutical company based in Switzerland. The company specializes in the discovery, development, and commercialization of innovative therapeutic proteins known as DARPins (Designed Ankyrin Repeat Proteins). These proteins are designed to target and inhibit disease-causing molecules, such as cancer cells or inflammatory factors.
Molecular Partners AG has a diverse pipeline of therapeutic candidates, with a focus on oncology, ophthalmology, and infectious diseases. The company has partnerships with several pharmaceutical companies, including Amgen, Allergan, and Novartis, to develop and commercialize its products.
The company's most advanced product candidate, MP0250, is being developed for the treatment of solid tumors and is currently in clinical trials. Molecular Partners AG also has a proprietary platform called DARPin X-Target, which allows for the discovery and development of DARPins that target specific disease-related molecules, enabling a more targeted and effective treatment approach.
Overall, Molecular Partners AG is committed to advancing the field of biopharmaceuticals and developing innovative therapies that have the potential to address unmet medical needs and improve patient outcomes.
Company Address: Wagistrasse 14 Zurich-Schlieren 8952
Company Phone Number: 755 77 00 Stock Exchange / Ticker: NASDAQ MOLN
|
0.3%